Document is current

Article History

Received: 22 November 2023

Accepted: 30 April 2024

First Online: 6 May 2024

Declarations

:

: The views expressed in this article are the authors’ own and do not necessarily represent the official positions of the National Cancer Institute or Moffitt Cancer Center. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or in the decision to publish the results.

: This study was performed in line with the principles of the Declaration of Helsinki and US Federal Policy for the Protection of Human Subjects. Approval was granted by the Advarra Institutional Review Board (January 19, 2021/Pro00049107).

: Informed consent was obtained from all individual participants included in the study. The authors affirm that human research participants provided informed consent for publication of their quotations.

: ASB reports membership on the advisory boards of Dicephera and Bayer outside the submitted work.JM reports funding from Merck and Morphogenesis Inc to Moffitt Cancer Center unrelated to this study.AAT reports contracted research grants with institution from Bristol Myers Squib, Novartis, Scholar Rock, Genentech-Roche, Regeneron, Sanofi-Genzyme, Nektar, Clinigen, Merck, Acrotech, Pfizer, Checkmate, OncoSec; personal consultant/advisory board fees from Bristol Myers Squibb, Merck, Easai, Instil Bio, Clinigen, Regeneron, Sanofi-Genzyme, Partner Therapeutics, Genentech/Roche, BioNTech, Concert AI, AstraZeneca, Pfizer outside the submitted work.NIK reports consulting fees from BMS, Merck, Jounce, Novartis, Regeneron, Genzyme, Iovance, Castle Biosciences, Nektar, Replimmune, and Instil Bio; research funding (to institute) from BMS, Merck, Celgene, Novartis, GSK, HUYA, Regeneron, Replimmune, Modulation Therapeutics; participation on a data safety monitoring board with Incyte, AstraZeneca; participation in a study steering committee with BMS, Nektar, Regerenon, Replimmune; and ownership of common stock in Bellicum, Amarin, and Asensus Surgical.HSLJ reports consulting fees from SBR Bioscience and grant funding from Kite Pharma outside the submitted work.